InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Mclaughlin Kevin F, Director. Officer active across 4 companies, notably Vericel Corp. In total, 20 filings have been published. Split: 1 buy · 1 sell. Total volume traded: €378k. History available since 23 September 2021. The latest transaction was disclosed on 12 August 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Mclaughlin Kevin F
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
7,000 股@ US$13.05Common StockSEC:0001140361-26-033143:0
7,000 股@ US$44.53Common StockSEC:0001140361-26-033143:1
3,500 股@ US$2.630.0005% mcap16.8% 占其流量Common StockSEC:0001140361-26-021656:0
3,200 股Common StockSEC:0001140361-26-018544:0
7,000 股@ US$2.630.0009% mcap33.2% 占其流量Common StockSEC:0001140361-26-005417:0
50,000 股@ US$2.50100.0% 占其流量Common StockSEC:0001193125-25-289825:0
标准退出：2026年2月17日 (T+90)
7,000 股@ US$2.6311.7% 占其流量Common StockSEC:0001140361-25-041647:0
7,000 股@ US$2.7613.8% 占其流量Common StockSEC:0001140361-25-029856:0
7,000 股@ US$2.7613.4% 占其流量Common StockSEC:0001140361-25-018156:0
3,200 股Common StockSEC:0001140361-25-017117:0
6,000 股@ US$3.7417.0% 占其流量Common StockSEC:0001140361-25-004765:0
7,000 股@ US$3.7419.4% 占其流量Common StockSEC:0001140361-24-047070:0
5,000 股@ US$3.7413.5% 占其流量Common StockSEC:0001140361-24-036617:0
3,200 股Common StockSEC:0001140361-24-024330:0
5,000 股Common StockSEC:0000899243-23-019494:0
5,000 股0Common StockSEC:0000950170-23-027990:0
2,600 股Common StockSEC:0001140361-23-021500:0
2,600 股Common StockSEC:0001593968-22-000890:0
10,681 股Common StockSEC:0001104659-21-142266:0
2,500 股@ US$30.17100.0% 占其流量Common StockSEC:0001179110-21-008935:0
20 条申报中的 20 条
About Mclaughlin Kevin F
Kevin F. McLaughlin is a Director at Vericel Corp, Decibel Therapeutics, Inc. and Invivyd, Inc., and he was also SVP, CFO and Treasurer at Acceleron Pharma INC. Across 18 filings in total, the 18 sampled filings run from 2021-09-24 to 2026-05-15 and show EUR 107934 of buying and EUR 0 of selling, with option exercise as the transaction type.
